<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05084027</url>
  </required_header>
  <id_info>
    <org_study_id>ZJU-HSCT-RIC</org_study_id>
    <nct_id>NCT05084027</nct_id>
  </id_info>
  <brief_title>Venetoclax Combining With Fludarabine and Melphalan as Conditioning Regimen for Allo-HSCT</brief_title>
  <official_title>Venetoclax Combining With Fludarabine and Melphalan as Conditioning Regimen Prior to Allogeneic Hematopoietic Stem Cell Transplantation for Older Patients With Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>First Affiliated Hospital of Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sir Run Run Shaw Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Second Affiliated Hospital, School of Medicine, Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhejiang Provincial People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The affiliated people's hospital of Ningbo University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital of Wenzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ningbo Hospital of Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Zhejiang Chinese Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>First Affiliated Hospital of Zhejiang University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      venetoclax combining with fludarabine and melphalan as conditioning regimen prior to&#xD;
      allogeneic hematopoietic stem cell transplantation for older patients with hematologic&#xD;
      malignancies&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It was a phase Ⅱ clinical trial of new designed reduced-intensity conditioning regimen for&#xD;
      older patients accepting allogeneic hematopoietic stem cell transplantation treatment. The&#xD;
      regimen consisted of venetoclax combining with fludarabine and melphalan.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 7, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>disease free survival</measure>
    <time_frame>2 year</time_frame>
    <description>2-year DFS</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>incidence of toxic reaction</measure>
    <time_frame>2 year</time_frame>
    <description>2-year incidence of toxic reaction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>2 year</time_frame>
    <description>2-year OS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cumulative incidence of relapse</measure>
    <time_frame>2 year</time_frame>
    <description>2-year incidence of relapse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of acute and or chronic graft verus host disease</measure>
    <time_frame>2 year</time_frame>
    <description>2-year incidence of cGVHD</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Hematologic Malignancy</condition>
  <condition>Older Patients</condition>
  <condition>Allogeneic Hematopoietic Stem Cell Transplantation</condition>
  <arm_group>
    <arm_group_label>treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>older patients accepting venetoclax combining with fludarabine and melphalan as conditioning regimen prior to allogeneic hematopoietic stem cell transplantation treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>venetoclax combining with fludarabine and melphalan</intervention_name>
    <description>Venetoclax 400mg/day，oral，day-8～day-2; Fludarabine, 30mg/m2/day，intravenous，d-7～d-3；Melphalan, 140mg/ m2/d，intravenous，day-2</description>
    <arm_group_label>treatment group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age older than 50 years&#xD;
&#xD;
          2. Patients diagnosed with acute myeloid leukemia, acute lymphoblastic leukemia,&#xD;
             myelodysplastic syndrome according to WHO diagnostic criteria.&#xD;
&#xD;
          3. Patients who achieved complete remission before transplantation.&#xD;
&#xD;
          4. Patients who have alternative donors and plane to accept allogeneic hematopoietic stem&#xD;
             cell transplantation treatment.&#xD;
&#xD;
          5. ECOG body status score 0-2.&#xD;
&#xD;
          6. Good organ function level: ANC (neutrophil absolute value &gt;=1.0x10^9/L; PLT&#xD;
             &gt;=30x10^9/L; HB &gt;=80g/L; Tibil &lt;=1.5 ULN; ALT / AST &lt;=2.5 ULN; bun / Cr &lt;=1.5 ULN;&#xD;
             LVEF &gt;=50%).&#xD;
&#xD;
          7. Patients who voluntarily participate in the clinical trial, understand the research&#xD;
             procedure and can sign the informed consent in writing.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who didn't achieved complete remission before transplantation (bone marrow&#xD;
             smear: proportion of primordial cells &gt;=5%) or any extramedullary recurrence.&#xD;
&#xD;
          2. Patients who were previously known to be resistant to venetoclax.&#xD;
&#xD;
          3. In patients with severe pulmonary insufficiency (obstructive and / or restrictive&#xD;
             ventilation disorders), the researchers evaluated the patients who could not tolerate&#xD;
             the super pretreatment scheme.&#xD;
&#xD;
          4. Patients with severe liver function impairment and liver function indexes (alt, TBIL)&#xD;
             more than 3 ULN were evaluated as intolerant of super pretreatment.&#xD;
&#xD;
          5. In patients with severe renal insufficiency, the renal function index (CR) is more&#xD;
             than 2 times of the upper limit of the normal value (ULN), or the 24-hour creatinine&#xD;
             clearance rate (CR) is less than 50ml / min, the researchers evaluated that they could&#xD;
             not tolerate the super pretreatment scheme.&#xD;
&#xD;
          6. In patients with severe active infection, the researchers evaluated that they could&#xD;
             not tolerate the pretreatment.&#xD;
&#xD;
          7. Patients who had allergic reactions or serious adverse reactions in the previous use&#xD;
             of pretreatment related drugs could not be included in the study.&#xD;
&#xD;
          8. Other reasons why the researchers could not be selected.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yi Luo, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>First Affilaated Hospital of Medical School of Zhejiang University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yi Luo, M.D.</last_name>
    <phone>+86057187233801</phone>
    <email>luoyijr@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yibo Wu, M.D.</last_name>
    <phone>+8619858876273</phone>
    <email>wuyibo7@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The first Affiliated Hospital of Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yi Luo, M.D.</last_name>
      <phone>+86057187233801</phone>
      <email>luoyijr@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>First Affiliated Hospital of Zhejiang Chinese Medicine University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Baodong Ye, MD</last_name>
      <phone>+8657187236706</phone>
      <email>13588453501@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Second Affiliated Hospital of Zhejiang University, School of Medicine</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yang Xu, MD</last_name>
      <phone>+8657187236706</phone>
      <email>zjuyujian@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Haowen Xiao, MD</last_name>
      <phone>+86057187236706</phone>
      <email>xiaohaowen@zju.edu.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhejiang Provincial People's Hospital</name>
      <address>
        <city>Hangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianping Lan, MD</last_name>
      <phone>+8657187236706</phone>
      <email>lanjp@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ningbo Hospital of Zhejiang University</name>
      <address>
        <city>Ningbo</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guifang Ouyang, MD</last_name>
      <phone>+86057187233801</phone>
      <email>luoyijr@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Affiliated People's Hospital of Ningbo University</name>
      <address>
        <city>Ningbo</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ying Lu, MD</last_name>
      <phone>+86057187236706</phone>
      <email>luying741107@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Wenzhou Medical University</name>
      <address>
        <city>Wenzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yi Chen, MD</last_name>
      <phone>+8657187236706</phone>
      <email>chenyi19527@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 7, 2021</study_first_submitted>
  <study_first_submitted_qc>October 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2021</study_first_posted>
  <last_update_submitted>October 20, 2021</last_update_submitted>
  <last_update_submitted_qc>October 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>First Affiliated Hospital of Zhejiang University</investigator_affiliation>
    <investigator_full_name>Yi Luo</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Venetoclax</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

